<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80529">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01804647</url>
  </required_header>
  <id_info>
    <org_study_id>GN-E-002</org_study_id>
    <nct_id>NCT01804647</nct_id>
  </id_info>
  <brief_title>Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease</brief_title>
  <acronym>LOMBARD</acronym>
  <official_title>A One Year Longitudinal Therapeutically Non-Interventional Study of MSRV-Env Burden in Multiple Sclerosis Patients (RRMS - SPMS - PPMS - CIS) as Assessed by PCR and ELISA in Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeNeuro Innovation SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GeNeuro Innovation SAS</source>
  <oversight_info>
    <authority>France Competent Authority: Agence Nationale de Sécurité du Médicament (ANSM)</authority>
    <authority>France Ethics Committee: Comité de Protection des Personnes Sud Méditerranée I (CPP)</authority>
    <authority>Switzerland Ethics Committee only: Commission d'Ethique de la Recherche Clinique Lausanne</authority>
    <authority>Spain Competent Authority: Agencia E. de Medicamentos y Productos Sanitarios (AEMPS)</authority>
    <authority>Cataluna Competent Authority: Subdireccion General de Farmacia: Productos Sanitarios</authority>
    <authority>Spain Ethics Committee: COMITÉ ÉTICO DE INVESTIGACIÓN CLÍNICA Y COMISIÓN DE PROYECTOS DE INVESTIGACIÓN DEL HOSPITAL UNIVERSITARI VALL D'HEBRON (CREC VHIR)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to explore evolution of MSRV expression by analyzing the levels of MSRV
      transcripts in blood, as well as the levels of the MSRV-Env protein in serum of MS patients.
      The study will be conducted over one year in four cohorts of patients with different forms
      of MS (remitting-relapsing MS i.e. RRMS, primary-progressive MS i.e. PPMS and
      secondary-progressive MS i.e. SPMS) and in clinically isolated syndrome (CIS) patients who
      have suffered a single clinical event but do not comply with diagnosis criteria for definite
      MS. The MSRV RNA and MSRV-Env protein levels will be correlated with the clinical evolution
      of patients and with the reverse transcriptase activity, inflammatory markers assessed by
      cytokines levels. A control group of healthy subjects will be included (the study, GN-E-003,
      is performed in parallel and is part of another dedicated protocol).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Monitor the levels of MSRV-Env expression in MS patients (according to McDonald criteria) of different diagnostic subgroups (RRMS, SPMS, PPMS, CIS)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Monitor the levels of MSRV-Env expression in MS patients (according to McDonald criteria) of different diagnostic subgroups (RRMS, SPMS, PPMS, CIS) over time using 3 approaches:
MSRV transcripts in PBMC;
MSRV transcripts in plasma;
MSRV-Env protein in serum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Associate the levels of MSRV-Env protein and transcripts</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associate the levels of MSRV-Env as assessed with the 3 approaches with MS relapses/exacerbations and/or clinical evolution (EDSS score) and /or treatment</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associate the levels of MSRV-Env as assessed with the 3 approaches with levels of inflammatory markers and reverse transcriptase activity</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare levels of MSRV-Env of MS patients to those obtained in a parallel study in Healthy Controls</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Sclerosis (MS)</condition>
  <condition>Relapsing-Remitting MS</condition>
  <condition>Primary Progressive MS</condition>
  <condition>Secondary Progressive MS</condition>
  <condition>Clinically Isolated Syndrome (CIS)</condition>
  <arm_group>
    <arm_group_label>25 RRMS patients</arm_group_label>
    <description>No study treatments administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 PPMS patients</arm_group_label>
    <description>No study treatments administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 SPMS patients</arm_group_label>
    <description>No study treatments administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 CIS patients</arm_group_label>
    <description>No study treatments administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No study treatments administered - blood draws only</intervention_name>
    <arm_group_label>25 RRMS patients</arm_group_label>
    <arm_group_label>25 PPMS patients</arm_group_label>
    <arm_group_label>25 SPMS patients</arm_group_label>
    <arm_group_label>25 CIS patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum and PBMC
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients coming to the Hospital for regular visits.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signature of an informed consent;

          -  Male or female between 18 and 60 years of age;

          -  Patients with PPMS (Revised McDonald criteria 2010) or patients with SPMS or CIS or
             patients with RRMS (Revised McDonald criteria 2010) ideally without IFN beta therapy
             at the T0 visit for RRMS patient only.

        Exclusion Criteria:

          -  Positive serology for hepatitis B or C or HIV;

          -  Acute infection at inclusion;

          -  Severe psychiatric disorder;

          -  Autoimmune disease other than MS;

          -  Pregnancy or breastfeeding;

          -  Heavy smokers i.e. more than 10 cigarettes per day;

          -  History of alcohol or drug abuse in the last 3 years;

          -  Participation in a clinical trial (within the last 3 months).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospices civils de Lyon - Service de Neurologie A - 59 Boulevard Pinel</name>
      <address>
        <city>Bron cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Timone - Service de Neurologie et CRMBM CNRS 7339 - 264, rue Saint Pierre</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari and Research Institute Vall d'Hebron - Servicio de Neuroimunologia de Nuestro Centro - Pg. Vall d'Hebron 119-129</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois - Dpt of Clinical Neurosciences - Neurology /Batiment 10-131 - Rue du Bugnon 46 -</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 28, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis (MS)</keyword>
  <keyword>Relapsing-Remitting MS</keyword>
  <keyword>Primary progressive MS</keyword>
  <keyword>Secondary progressive MS</keyword>
  <keyword>Clinically Isolated Syndrome (CIS)</keyword>
  <keyword>Multiple Sclerosis associated RetroVirus (MSRV)</keyword>
  <keyword>MSRV envelop protein (MSRV-Env)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
